Saturday, May 3, 2014

Navigation MEDICA Magazine MEDICA Magazine Top Topic of the Month Theme Preview 2014 May 2014: Mobi


Navigation MEDICA Magazine MEDICA Magazine Top Topic of the Month Theme Preview 2014 May 2014: Mobile Health & IT April 2014: Emergency Medicine selective mutism March 2014: training in February 2014: Cancer January 2014: Surgery Year Archive Interviews Overview of Interviews Interviews to innovations in health policy Interviews Concerning Business Industry News Scene & Company News Product News Research & Technology Economy & Markets selective mutism Politics & Associations Newsletter Newsletter Archive 30/04/2014: Epileptic encephalopathy 23/04/2014: Stem cells from space 16/04/2014: nostrils bred 09/04/2014: Workplace Health selective mutism 02/04/2014 : 03/26/2014 save lives: Health selective mutism from Space 19.03.2014: Little Helpers 3/12/2014: Medical for children 03/05/2014: selective mutism For the health qualified 2/26/2014: The MRT for the office 02.19.2014: selective mutism Contest: I Have You! Older Newsletter Archives Media Center Videos Recent Videos Wallpapers Reports Exhibitor Interviews Company & Product Videos Photo Galleries The latest photo galleries retrospect of the MEDICA 2013 Mercy Ships - Ships that help bring retrospect of the MEDICA 2012 Review of MEDICA 2011 photo spreads GOOD TO KNOW world market index medical experts portals Medical Societies German Medical Event Calendar World of MEDICA
"A life extension of almost four months is significantly and substantially with such a pronounced tumor disease. And that with a largely side-effect selective mutism free drug. The study demonstrates the effectiveness and gives hope for further development, "said Professor Michael Stoeckle, the 2nd Vice-President of the German Society for Urology Association (DGU). At the Phase III study enrolled from April 2008 about 1,200 patients in 13 countries took part, in which, despite anti-hormonal therapies and docetaxel chemotherapy, the tumor cells grew again. Two-thirds received abiraterone in combination with prednisone, a third placebo plus prednisone. While the patients in the abiraterone selective mutism group statistical average lived 14.8 months, there were in the placebo group 10.9 months. Also a longer progression-free survival in abiraterone versus placebo and a significantly selective mutism higher response rate in lowering the PSA were highlighted as another first results. The tolerability of the oral preparation is classified selective mutism as good for older patients. In the study, no significant selective mutism difference in toxicities between selective mutism abiraterone and placebo were observed. In Germany, selective mutism five institutions were involved in the study, including selective mutism urology at the University Hospital Aachen, Campus Benjamin Franklin, Charité in Berlin, University Hospital Carl Gustav Carus at the Technical University of Dresden and Urology at the University Hospital of Saarland, Homburg / Saar. In the patients of the study, the suppression of the production of the sex hormone testosterone had no longer achieved by most medical, surgical castration today hardly the desired effect. The prostate had become castration-resistant and formed new metastases. In urology, the concept of castration-resistant prostate selective mutism cancer since 2008 replaced (CRPC) are increasingly the terms "hormonrefraktäres" or "androgenunabhängiges" prostate cancer. selective mutism It results from the realization that the prostate cancer on androgen remain despite elimination of the gonads, especially the testicles sensitive. Even the lowest androgen levels, which are formed in the adrenal cortex or the tumor cells themselves, can thus trigger a renewed tumor growth. The chemotherapy based on docetaxel, selective mutism otherwise the therapeutic bullet at this stage of prostate cancer had tumor growth no longer stopped in the patients at the end. The drug abiraterone is an irreversible inhibitor of the enzyme cytochrome P-17, which in the intracellular production of the androgen selective mutism testosterone plays a central role. Abiraterone blocks the androgen in the body. "For final assessments, it is still too early, but the study appears to mark a significant selective mutism development. We need to see is to reach more refinements whether with or in combination with other medicines. The drug gives hope, "says Stoeckle. Abiraterone could change and expand selective mutism the existing treatment approaches selective mutism in CRPC decisive in his view. With appropriate development and without development of resistance is conceivable in view of the effectiveness and good tolerability even a displacement of cytostatic therapies. This is all the more likely if a second ongoing phase III trial of abiraterone confirm the previous results. At this second study started in April 2009 to take part in CRPC patients without chemotherapeutic treatment. MEDICA.de; Source: Englis

No comments:

Post a Comment